Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 8, 2014, Pages 1111-1119

  Carlsson, Anders ^a   Nair, Viswam S ^b   Luttgen, Madelyn S ^a   Keu, Khun Visith ^c   Horng, George ^d   Vasanawala, Minal ^b,e   Kolatkar, Anand ^a   Jamali, Mehran ^b   Iagaru, Andrei H ^b   Kuschner, Ware ^b,e   Loo Jr , Billy W ^b   Shrager, Joseph B ^b,e   Bethel, Kelly ^f   Hoh, Carl K ^g   Bazhenova, Lyudmila ^g   Nieva, Jorge ^h   Kuhn, Peter ^a   Gambhir, Sanjiv S ^b,e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f SCRIPPS CLINIC   (United States)

^g UNIVERSITY OF SAN DIEGO   (United States)

^h BILLINGS CLINIC   (United States)

Author keywords

CTC; Diagnostic; Lung nodule; NSCLC; Stage I

Indexed keywords

CD45 ANTIGEN; CYTOKERATIN; FLUORODEOXYGLUCOSE F 18; 4',6 DIAMIDINO 2 PHENYLINDOLE; INDOLE DERIVATIVE; KERATIN; PTPRC PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CASE CONTROL STUDY; CIRCULATING TUMOR CELL; CIRCULATING TUMOR MICROEMBOLI; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EVALUATION STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PET-CT SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TASK PERFORMANCE; AREA UNDER THE CURVE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EMBOLISM; LUNG NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; TUMOR EMBOLISM; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD45; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; EMBOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84905814502     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000235     Document Type: Article

References (40)

1. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
2. Schultz EM, Sanders GD, Trotter PR, et al. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax 2008;63:335-341.
3. Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013;5:207ra142.
4. Asworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Med J 1869;14:146-147.
5. Takahashi M. An experimental study of metastasis. J Pathol Bacteriol 1915;20:1-13.
6. Romsdahl MD, Chu EW, Hume R, Smith RR. The time of metastasis and release of circulating tumor cells as determined in an experimental system. Cancer 1961;14:883-888.
7. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
8. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-1430.
9. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in nonmetastatic breast cancer: a prospective study. Lancet Oncol 2012;13: 688-695.
10. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-1563.
11. Tanaka F YK, Hasegawa S. Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives. Lung Cancer: Targets and Therapy. 2010;1:77-84.
12. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009;15:6980-6986.
13. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-584.
14. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-1239.
15. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011;17:827-835.
16. Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004;101:10501-10504.
17. Kuhn P, Bethel K. A fluid biopsy as investigating technology for the fluid phase of solid tumors. Phys Biol 2012;9:010301.
18. Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012;9:016003.
19. Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med 2009;133:1468-1471.
20. Lazar DC, Cho EH, Luttgen MS, et al. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostatetumor- derived LNCaP cell line. Phys Biol 2012;9:016002.
21. Nieva J, Wendel M, Luttgen MS, et al. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol 2012;9:016004.
22. Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage nonsmall cell lung cancer: a glimpse into lung cancer biology. Phys Biol 2012;9:016005.
23. Cho EH, Wendel M, Luttgen M, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 2012;9:016001.
24. Nair VS, Keu KV, Luttgen MS, et al. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatmentnaive non-small cell lung cancer. PLoS One 2013;8:e67733.
25. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e93S-120S.
26. MacMahon H, Austin JH, Gamsu G, et al.; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237:395-400.
27. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013;266:304-317.
28. Ettinger DS, Akerley W, Borghaei H, et al.; NCCN (National Comprehensive Cancer Network). Non-small cell lung cancer. J Natl Compr Canc Netw 2012;10:1236-1271.
29. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-1438.
30. Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602.
31. Shankar LK, Hoffman JM, Bacharach S, et al.; National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-1066.
32. Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Statist Soc B 1996;58:267-288.
33. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
34. Picard R, Cook D. Cross-validation of regression models. J Am Stat Assoc 1984;79:575-583.
35. Ihaka S, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
36. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36:889-894.
37. Brandt B, Junker R, Griwatz C, et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 1996;56:4556-4561.
38. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904.
39. Pantel K, Denève E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem 2012;58:936-940.
40. Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013;110:21083-21088.